Kyverna Therapeutics, Inc. Common Stock (KYTX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $7.13 (+1.28%), Market cap $0.54B, 52-week low–high $2.27 ~ $11.25.
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAI
Financial statements, price targets, institutional (13F) holdings and related news for Kyverna Therapeutics, Inc. Common Stock are updated in real time on BlackAll Trade.
Kyverna Therapeutics, Inc. Common Stock trades at $7.13 (+1.28%). Real-time quotes and charts are available on BlackAll Trade.
Kyverna Therapeutics, Inc. Common Stock has a market cap of about $0.54B.
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD1